Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical StudyMitsutoshi Satoh1*, Ami Kuzuu1, Hirokazu Doi2, Toru Masaka2, Ryuji Sakakibara3
- *Corresponding Author:
- Mitsutoshi Satoh
Department of Toxicology and Pharmacology
Division of Pharmacy Practice
Meiji Pharmaceutical University
2-522-1 Noshio, Kiyose, Tokyo 204-8588,Japan.
E-mail: [email protected]
Received: 19 August 2015 Accepted: 02 September 2015 Published: 10 September 2015
As L-DOPA replacement is the main treatment for patients with Parkinson’s disease, monitoring of the blood dopamine (DA) concentration is useful for prediction of peripheral adverse events. We studied patients with advanced Parkinson’s disease for whom L-DOPA and an NMDA receptor antagonist, amantadine, had been prescribed since 2006 at Sakura Hospital, Toho University Medical Center. The blood concentrations of L-DOPA, DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-O-methyldopa (3-OMD) before and at 1, 2 and 3 hours after administration of L-DOPA and amantadine were measured using a high-performance liquid chromatography-electrochemical detector (HPLC-ECD) system. We used hospital medical records to establish the age of the patients, and their gender, Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores, L-DOPA dosing regime, use of amantadine in combination with L-DOPA, and adverse events.